QIBA CT Volumetry Biomarker Ctte (BC) Call  
17 July 2017 at 11 AM CT  
Call Summary

In attendance:

<table>
<thead>
<tr>
<th>RSNA:</th>
<th>RSNA:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Goldmacher, MD, PhD, MBA  (Co-Chair)</td>
<td>Kevin O’Donnell, MAsc</td>
</tr>
<tr>
<td>Jenifer Siegelman, MD, MPH  (Co-Chair)</td>
<td>Eric Perlman, MD</td>
</tr>
<tr>
<td>Andrew Buckler, MS</td>
<td>Nicholas Petrick, PhD</td>
</tr>
<tr>
<td>Charles Fenimore, PhD</td>
<td>Marthony Robins, PhD</td>
</tr>
<tr>
<td>Rudresh Jarecha, MBBS</td>
<td>Ying Tang, PhD</td>
</tr>
<tr>
<td>Jenifer Siegelman, MD, MPH  (Co-Chair)</td>
<td>James Mulshine, MD</td>
</tr>
<tr>
<td>Andrew Buckler, MS</td>
<td>Nancy Obuchowski, PhD</td>
</tr>
<tr>
<td>Charles Fenimore, PhD</td>
<td>Michael O’Connor, PhD</td>
</tr>
</tbody>
</table>

Discussion included the following:

Profile Technical Confirmation Feedback:

- Mr. O’Donnell has summarized and categorized all Profile feedback in a more manageable format, available for viewing on the CT Volumetry BC page of the QIBA wiki:  
  https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdla30U/edit?usp=sharing
- A small targeted TF comprised of various stakeholders, e.g., Drs. Goldmacher, Petrick, Robins, and Mr. O’Donnell, has been meeting independently via teleconference to resolve the few remaining open issues
  - They have divided issues into the following categories:
    - Comments that can be finalized
    - Comments that can be resolved with some minor editing
    - Comments that need additional group discussion
- Drs. Siegelman and Samei are working on the more difficult discussion points and are turning them into proposals for the BC’s consideration
- Mr. O’Donnell reviewed comments from the technical confirmation testing sites and indicated that some of the resolutions were routine (R), feasible/will perform (FW), feasible but won’t be performed (FN), or not feasible (NF)
- Currently, 12 discussion items remain

Additional topics:

- There was substantial discussion regarding the requirements for reporting amount and timing of contrast used
- Concerns include how critical repeatable contrast administration is and how to make any reporting/documenting requirements practical
- It was decided that “no contrast” would also be an acceptable protocol and that informative normative text would be provided in the discussion section so that contrast would not be required

Action items:

- Additional spreadsheets for a regression module and coordinates for RIDER tumors are being compiled by Mr. Tervé
- Drs. Samei, Robins, and Supanich to collaborate on Z-axis resolution and MTF language for the Profile
- Those interested in a Texture/ Morphology TF are asked to respond via a Google link:  
  https://goo.gl/forms/gEMkNNZuocj7twlk1

Next Call:  TBD by co-chairs
AAPM is scheduled for July 30 – August 3